Somanetics (SMTS) Reports Mixed Q3 Results; Reaffirms Guidance
More News related to SMTS
- Somanetics (SMTS) Signs with Raba Equity for Johns Hopkins Cerebral Autoregulation Tech
- Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University
- Somanetics (SMTS) Reports Mixed Q3 Results; Reaffirms Guidance
- Somanetics (SMTS) Files Patent Infringement Suit Against CAS Medical (CASM)
- Somanetics (SMTS) Announces New FDA 510(K) Clearance
Somanetics Corp. (Nasdaq: SMTS) reports Q3 EPS of $0.17, 3 cents better than the analyst estimate of $0.14. Revenue for the quarter was $12.5 million, which compares to the estimate of $13.09 million.
Reaffirms outlook.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.27Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
